Immune Modulation by Exosomes in COVID-19
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorUniversity of Ulm
About this trial
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
Eligibility criteria
Qualifiers
Critically ill COVID-19 patients with lung dysfunction
COVID-19 WHO severity degree >= 4, ARDS (WHO Definition 13 March 2020)
Body weight > 50 kg
Informed consent
Disqualifiers
Pregnant or breast feeding women
Trial design
Treatments tested in this trial
- Application of exosomes in a whole blood assay
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov